**Alphabet's Life Sciences Business, Verily, Seeks New Path as Independent Entity** Verily, Alphabet's life sciences business, is undergoing significant changes as it restructures and raises $300 million in funding. This investment round will enable Verily to transition from a limited liability company (LLC) to a corporation, renaming itself Verily Health Inc. As a result, Alphabet will no longer have a controlling stake in the business, instead holding a minority stake. The move is part of a broader shift in focus for Verily, which has been working on integrating **Artificial Intelligence (AI)** into its operations. In a statement, Chairman and CEO Stephen Gillett emphasized the importance of AI in delivering the next generation of healthcare. "From research to care, our customers need solutions that bring the best of clinical and scientific rigor together with AI to deliver the next generation of healthcare - one that is as precise as it is personal," Gillett said. Verily's history dates back to 2015, when Google Life Sciences was rebranded as Verily. This change coincided with Google's rebranding as Alphabet. Since then, Verily has worked on a variety of projects, including the development of eye scans to predict heart disease and the creation of an opioid addiction center. In 2025, the company closed its medical device division, which some saw as a signal of its increasing focus on AI-driven initiatives. The restructuring and funding round are expected to support Verily's ongoing efforts to leverage AI in healthcare. With a new corporate structure in place, the company is poised to continue its work in this area, with a focus on delivering precise and personalized healthcare solutions to its customers.